Latest Biotech News

FDA approved Takeda’s Mimrylo (rusfertide) for polycythemia vera, clearing the engineered peptide for a rare blood cancer with limited treatment options. The approval expands a commercial runway...

Eli Lilly agreed to buy Merida Biosciences for up to $2.875 billion to add a targeted autoantibody-degradation platform to its immunology pipeline. The deal gives Lilly a technology designed to...

ARCH Venture Partners outlined plans to target a new $3 billion raise for its latest fund, signaling continued appetite for large-scale biotech venture investment. The vehicle would be ARCH’s 14th...

Nine additional biopharma companies signed most-favored-nation (MFN) pricing agreements with the Trump administration, bringing expansion of the policy beyond the largest drugmakers. The new...

IQVIA data showed that Medicare-negotiated drug price cuts did not translate into immediate access improvements for many patients in early 2026. In the first quarter after maximum fair prices took...

A Tufts Center for the Study of Drug Development analysis warned of a widening “execution translation gap” between identifying clinical trial risks and implementing corrective action. The study...

Researchers unveiled a gene-activation platform designed to operate inside the body, targeting a delivery limitation that has constrained standard CRISPR-based systems. The approach uses a smaller...

Electra Therapeutics filed for an IPO to fund Phase 2/3 development in immunology and oncology. The South San Francisco biotech plans to list on Nasdaq under ticker ETRA after the Labor Day...

Revolution Medicines’ FDA approval for its oral pancreatic cancer therapy highlighted a disconnect between clinical milestones and near-term equity reaction. The FDA cleared Rasonque...

Takeda won FDA approval for Mimrylo (rusfertide) in polycythemia vera, with the engineered peptide originally developed by Protagonist Therapeutics. The approval follows a label broader than some...

Eli Lilly agreed to buy Merida Biosciences for $2.875 billion, betting on a more selective immunology approach focused on degrading pathogenic autoantibodies. The deal adds Merida’s Graves disease...

A U.S. Court of Appeals panel upheld a lower-court ruling blocking compounders’ challenges to the FDA’s removal of Eli Lilly and Novo Nordisk GLP-1 drugs from the agency’s shortage list. The court...

The White House announced nine additional “most-favored nation”-style voluntary pricing deals with drugmakers, adding companies including Alcon, Astellas, BridgeBio, CSL, Sun Pharma, Kyowa Kirin,...

New IQVIA analysis reports that Medicare drug price cuts tied to the 2026 negotiation program did not automatically translate into patient access. In the first quarter of 2026, nearly a quarter of...

Researchers at the Medical University of South Carolina Hollings Cancer Center identified a resistance mechanism in triple-negative breast cancer involving lysyl oxidase (LOX) and reported a...

Nautilus shifted strategy after ongoing reagent challenges delayed proteome-scale ambitions. The company said it is redirecting most R&D resources toward a targeted protein assay market it views...

Electra Therapeutics filed for an IPO on Nasdaq to fund clinical development of its immunology and cancer pipeline. The company plans to list under ticker ETRA and intends to deploy proceeds to...

DARPA awarded up to $11.312 million to UC San Diego to develop engineered red blood cells intended to temporarily improve oxygen delivery. Over three years, the project will test the concept of...

A Tufts Center for the Study of Drug Development analysis argues that sponsors and CROs can spot clinical trial risks but struggle to execute coordinated corrective action when problems emerge....

FDA has cleared Takeda’s rusfertide (marketed as Mimrylo) for polycythemia vera, expanding the label for a rare blood cancer treatment originally developed by Protagonist Therapeutics. The...